AbbVie (NYSE:ABBV) delivered a robust full-year performance for 2025, proving that its strategy to replace the aging blockbuster Humira is ahead of schedule as its newer immunology and neuroscience portfolios hit record highs.
The North Chicago-based drugmaker reported Wednesday that full-year net revenues rose 8.6% to $61.16 billion.
The performance was anchored by the continued dominance of Skyrizi, which generated a staggering $17.56 billion for the year, and Rinvoq, which brought in $8.30 billion.
Together, the two therapies have successfully cushioned the impact of Humira’s decline, which saw its global revenue slide to $4.54 billion amid intense biosimilar competition.
On a GAAP basis, the company reported full-year diluted EPS of $2.36, heavily impacted by a $2.76 per-share headwind from acquired in-process R&D (IPR&D) and milestone payments related to its aggressive deal-making.
Stripping out these one-time costs, adjusted diluted EPS reached $10, meeting the high end of the company’s internal targets.
AbbVie's pipeline also saw significant milestones in 2025.
The company secured FDA approval for Epkinly in relapsed or refractory follicular lymphoma, marking the first-ever bispecific antibody combination therapy in the space.